This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
QIAGEN & Bristol-Myers Squibb Partner on Cancer Research
by Zacks Equity Research
QIAGEN N.V. (QGEN) has made significant advancement in the field of cancer research through the use of its revolutionary next-generation sequencing (NGS) technology.
Quintiles IMS Holdings (Q) Holds Secondary Offering (revised)
by Zacks Equity Research
Q held a secondary offering of 10.6m shares, of which they repurchased $300m worth.
Mead Johnson's Shareholders Approve Reckitt Benckiser Deal
by Zacks Equity Research
Mead Johnson's (MJN) stockholders have okayed the impending merger with Reckitt Benckiser Group.
Hill-Rom Holdings Hits 52-Week High on Solid Product Line
by Zacks Equity Research
Share price of Batesville, IN-based Hill-Rom Holdings, Inc. (HRC) scaled a new 52-week high of $78.51 on Jun 1.
The Cooper Companies (COO) Beats Earnings Estimates in Q2
by Zacks Equity Research
The Cooper Companies Inc. (COO) reported adjusted earnings of $2.50 in second-quarter fiscal 2017, surpassing the Zacks Consensus Estimate by 25 cents and improving from $2.05 in the year-ago quarter.
Edwards Lifesciences' TAVR & International Prospects Solid
by Zacks Equity Research
On Jun 2, we issued an updated research report on leading molecular diagnostic company, Edwards Lifesciences Corporation (EW).
Patterson Companies Grapples With Multiple Issues: Dump Now?
by Zacks Equity Research
On Jun 2, we issued an updated research report on St. Paul, MN-based The Patterson Companies (PDCO), a leading distributor of the dental, companion-pet veterinarian and rehabilitation supply markets.
Medtronic Starts PRODIGY Study on Respiratory Compromise
by Zacks Equity Research
Medtronic plc (MDT) recently introduced a new global study on opioid induced respiratory depression (OIRD), a preventable form of respiratory compromise.
Genomic Health to Unveil Oncotype DX Study Results at ASCO
by Zacks Equity Research
Global cancer research company Genomic Health, Inc. (GHDX) will be presenting results from eight Oncotype DX studies at American Society of Clinical Oncology (ASCO) in Chicago.
3 Medical Device Stocks with Solid Potential to Buy Now
by Zacks Equity Research
The Medical Device industry has been riding high on optimism of late, courtesy of the Senate's latest decision to lacerate the Affordable Care Act (ACA) by the end of July.
Align Technology Upgrades iTero Element Intraoral Scanners
by Zacks Equity Research
Based in California, leading dental product maker Align Technology, Inc. (ALGN) recently announced a software upgrade to its iTero Element intraoral scanners.
UnitedHealth Unit Taps Connecticut Orthopedic Surgery Market
by Zacks Equity Research
Surgical Care Affiliates, Inc, a part of UnitedHealth Group's Optum unit, recently partnered with Western Connecticut Orthopedic Surgery Center by making an equity investment in the latter.
LabCorp Trades Down on Weak 2017 View, Reimbursement Woes
by Zacks Equity Research
On May 30, we issued an updated research report on Burlington, NC-based Laboratory Corporation of America Holdings (LH).
Becton, Dickinson at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Becton, Dickinson and Company (BDX), based in Franklin Lakes, NJ, Becton, scaled a new 52-week high of $188.48 on May 30, eventually closing a bit lower at $188.07.
Baxter International at a 52-Week High on Solid Product Line
by Zacks Equity Research
Share price of Deerfield, IL-based Baxter International Inc. (BAX) scaled a new 52-week high of $59.49 on May 30, eventually closing a bit lower at $59.35.
Intuitive Surgical da Vinci X Surgical System Okayed by FDA
by Zacks Equity Research
Headquartered in Sunnyvale, CA, Intuitive Surgical Inc. (ISRG) recently announced that the da Vinci X Surgical System, an upgrade to its flagship da Vinci Xi surgical platform, has been cleared by the FDA.
Boston Scientific Trades Up on Strong Q1 amid Recall Issues
by Zacks Equity Research
On May 29 2017, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).
IDEXX Laboratories Global Growth Solid amid Currency Woes
by Zacks Equity Research
On May 29, we issued an updated research report on leading molecular diagnostic company, IDEXX Laboratories, Inc. (IDXX).
Quintiles IMS Holdings (Q) to Repurchase 10.6M Common Share
by Zacks Equity Research
Quintiles IMS Holdings, Inc. (Q) announced that it will repurchase 10,571,003 shares of its common stock.
NuVasive Aims for Innovation, Global Growth amid Woes
by Zacks Equity Research
On May 29, we issued an updated research report on San Diego, CA-based NuVasive, Inc. (NUVA).
Inogen (INGN) Hits a 52-Week High on Solid Q1, Upbeat View
by Zacks Equity Research
Shares of Inogen Inc. (INGN) rallied to a new 52-week high of $89.54 on May 26, eventually closing a tad bit lower at $87.93. This represents a strong one-year return of about 84.6%, much better than the S&P 500's return of roughly 9.7%.
Varian Medical at a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Varian Medical Systems Inc. (VAR), headquartered in Palo Alto, CA, scaled a new 52-week high of $97.96 on May 26, eventually closing a bit lower at $97.87.
Thermo Fisher on an Acquisition Spree, Competition Rife
by Zacks Equity Research
On May 29, we issued an updated research report on Waltham, MA-based Thermo Fisher Scientific, Inc. (TMO), a scientific instrument maker and a world leader in serving science.
Myriad Genetics Gets Extended Coverage for Prolaris Test
by Zacks Equity Research
Molecular diagnostics and personalized medicine major Myriad Genetics, Inc. (MYGN) recently received extended Medicare coverage for its Prolasis test.
Why WellCare (WCG) Stock Should Be in Your Portfolio Now
by Zacks Equity Research
Leading managed care company WellCare Health Plans, Inc.'s (WCG) business strategies should continue to support growth.